<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39398078</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Deciphering angiotensin converting enzyme 2 (ACE2) inhibition dynamics: Carnosine's modulatory role in breast cancer proliferation - A clinical sciences perspective.</ArticleTitle><Pagination><StartPage>e38685</StartPage><MedlinePgn>e38685</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e38685</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e38685</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Angiotensin-converting enzyme 2 (ACE2) is a pivotal molecular nexus linking novel coronavirus disease to breast cancer. In-silico investigations have repurposed carnosine for both these conditions based on its potential ACE2 inhibitory properties.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Utilizing an ACE2 inhibitor screening kit, we determined the inhibitory range of carnosine doses. Subsequently, we examined the effect of carnosine on ACE2 expression in supernatants from various breast cancer cell lines (MCF-7, MDA-MB-231, and EMT-6). Additionally, we compared ACE2 activity in cell line pellets with and without carnosine and a putative ACE2 activator using a fluorometric activity assay kit. Finally, we performed a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay across overlapping concentrations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Carnosine exhibited dose-dependent ACE2 inhibition within the 100-300 mM range. ACE2 expression significantly diminished after exposure to carnosine for 2 and 24 h in MDA-MB-231 and MCF-7 cell lines, respectively. MTT assay unveiled notable antiproliferative effects in MDA-MB-231 (50 % survival at approximately 265 mM) and EMT-6 cell lines (unquantifiable 50 % survival dose). Conversely, the MCF-7 cell line displayed a modest increase in proliferation (Effective concentration 50-186 mM, ∼40 % increased survival).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This pioneering study delineates evident dose-dependent ACE2 inhibition by carnosine. Moreover, it unveils the modulatory impact of this ACE2 inhibitor in breast cancer cell lines. Carnosine demonstrated a significant antiproliferative effect on aggressive cell lines while sparing luminal cell lines from substantial toxic or proliferative effects.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Melhem</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Applied Science Private University. Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saadah</LastName><ForeName>Loai M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Applied Science Private University. Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attallah</LastName><ForeName>Zeena S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Applied Science Private University. Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansi</LastName><ForeName>Iman A</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, Hashemite University, Zarqa, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamed</LastName><ForeName>Saja H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Hashemite University, Zarqa, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talib</LastName><ForeName>Wamidh H</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Faculty of Allied Medical Sciences, Applied Science Private University. Amman, Jordan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin-converting enzyme 2 (ACE2)</Keyword><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">Carnosine</Keyword><Keyword MajorTopicYN="N">Inhibitor</Keyword><Keyword MajorTopicYN="N">Luminal</Keyword><Keyword MajorTopicYN="N">MCF-7. MDA-MB-231</Keyword><Keyword MajorTopicYN="N">Triple negative</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39398078</ArticleId><ArticleId IdType="pmc">PMC11471176</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e38685</ArticleId><ArticleId IdType="pii">S2405-8440(24)14716-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vatansev H., Kadiyoran C., Cumhur Cure M., Cure E. COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection. Med. Hypotheses. 2020 Oct;143 doi: 10.1016/j.mehy.2020.110091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110091</ArticleId><ArticleId IdType="pmc">PMC7347308</ArticleId><ArticleId IdType="pubmed">32663742</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar H.S., Nayak A., Gavel P.K., Jha H.C., Bhagwat S., Sharma R. Cross talk between COVID-19 and breast cancer. Curr. Cancer Drug Targets. 2021;21(7):575–600. doi: 10.2174/1568009621666210216102236.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568009621666210216102236</ArticleId><ArticleId IdType="pubmed">33593260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhari V.K., Kumar D., Kumar S., Mishra R. SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes. Biochem Biophys Rep. 2020 Dec;24 doi: 10.1016/j.bbrep.2020.100844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrep.2020.100844</ArticleId><ArticleId IdType="pmc">PMC7643628</ArticleId><ArticleId IdType="pubmed">33178900</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair M.G., Prabhu J.S., Ts S. High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis. Cancer Treat Res Commun. 2021;27 doi: 10.1016/j.ctarc.2021.100321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctarc.2021.100321</ArticleId><ArticleId IdType="pmc">PMC7825889</ArticleId><ArticleId IdType="pubmed">33517235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Chen L., Shen J., Mei X., Yao J., Chen T., Zhou Y. The potential role of abnormal angiotensin-converting enzyme 2 expression correlated with immune infiltration after SARS-CoV-2 infection in the prognosis of breast cancer. Aging (Albany NY) 2021 Aug 19;13(17):20886–20895. doi: 10.18632/aging.203418.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203418</ArticleId><ArticleId IdType="pmc">PMC8457607</ArticleId><ArticleId IdType="pubmed">34413267</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo X., Ren S., Zhang H., Tian J., Tian R., Han B., Liu H., Dong Q., Wang Z., Cui Y., Niu R., Zhang F. Chemotherapy induces ACE2 expression in breast cancer via the ROS-AKT-HIF-1α signaling pathway: a potential prognostic marker for breast cancer patients receiving chemotherapy. J. Transl. Med. 2022 Nov 5;20(1):509. doi: 10.1186/s12967-022-03716-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03716-w</ArticleId><ArticleId IdType="pmc">PMC9636712</ArticleId><ArticleId IdType="pubmed">36335375</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash M.D., Fraser S., Boer J.C., Plebanski M., de Courten B., Apostolopoulos V. Anti-cancer effects of carnosine-A dipeptide molecule. Molecules. 2021 Mar 16;26(6):1644. doi: 10.3390/molecules26061644.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26061644</ArticleId><ArticleId IdType="pmc">PMC8002160</ArticleId><ArticleId IdType="pubmed">33809496</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaafar P.M.E., El-Salamouni N.S., Farid R.M., Hazzah H.A., Helmy M.W., Abdallah O.Y. Pegylated liquisomes: a novel combined passive targeting nanoplatform of L-carnosine for breast cancer. Int J Pharm. 2021 Jun 1;602 doi: 10.1016/j.ijpharm.2021.120666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120666</ArticleId><ArticleId IdType="pubmed">33933646</ArticleId></ArticleIdList></Reference><Reference><Citation>Farid R.M., Gaafar P.M.E., Hazzah H.A., Helmy M.W., Abdallah O.Y. Chemotherapeutic potential of L-carnosine from stimuli-responsive magnetic nanoparticles against breast cancer model. Nanomedicine (Lond). 2020 Apr;15(9):891–911. doi: 10.2217/nnm-2019-0428. Epub 2020 Apr 2.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm-2019-0428</ArticleId><ArticleId IdType="pubmed">32238029</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelletto V., Edwards-Gayle C.J.C., Greco F., Hamley I.W., Seitsonen J., Ruokolainen J. Self-assembly, tunable hydrogel properties, and selective anti-cancer activity of a carnosine-derived lipidated peptide. ACS Appl. Mater. Interfaces. 2019 Sep 18;11(37):33573–33580. doi: 10.1021/acsami.9b09065. Epub 2019 Sep. 3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.9b09065</ArticleId><ArticleId IdType="pmc">PMC7007010</ArticleId><ArticleId IdType="pubmed">31407889</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein M.M.A., Abdelfattah-Hassan A., Eldoumani H., Essawi W.M., Alsahli T.G., Alharbi K.S., Alzarea S.I., Al-Hejaili H.Y., Gaafar S.F. Evaluation of anti-cancer effects of carnosine and melittin-loaded niosomes in MCF-7 and MDA-MB-231 breast cancer cells. Front. Pharmacol. 2023 Sep 21;14 doi: 10.3389/fphar.2023.1258387.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1258387</ArticleId><ArticleId IdType="pmc">PMC10552532</ArticleId><ArticleId IdType="pubmed">37808196</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldi S., Perrucci E., Fulcheri C.P.L., Mariucci C., Chierchini S., Ingrosso G., Falcinelli L., Podlesko A.M., Merluzzi M., Bini V., Aristei C. Zinc-L-carnosine prevented dysphagia in breast cancer patients undergoing adjuvant radiotherapy: results of a phase III randomized trial. Breast J. 2020 Sep;26(9):1882–1884. doi: 10.1111/tbj.13855. Epub 2020 May 7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tbj.13855</ArticleId><ArticleId IdType="pubmed">32383225</ArticleId></ArticleIdList></Reference><Reference><Citation>Maugeri S., Sibbitts J., Privitera A., Cardaci V., Di Pietro L., Leggio L., Iraci N., Lunte S.M., Caruso G. The anti-cancer activity of the naturally occurring dipeptide carnosine: potential for breast cancer. Cells. 2023 Nov 8;12(22):2592. doi: 10.3390/cells12222592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12222592</ArticleId><ArticleId IdType="pmc">PMC10670273</ArticleId><ArticleId IdType="pubmed">37998326</ArticleId></ArticleIdList></Reference><Reference><Citation>Baye E., Ukropcova B., Ukropec J., Hipkiss A., Aldini G., de Courten B. Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease. Amino Acids. 2016 May;48(5):1131–1149. doi: 10.1007/s00726-016-2208-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-016-2208-1</ArticleId><ArticleId IdType="pubmed">26984320</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. 2010 Dec 1;49(11):1603–1616. doi: 10.1016/j.freeradbiomed.2010.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2010.09.006</ArticleId><ArticleId IdType="pmc">PMC2990475</ArticleId><ArticleId IdType="pubmed">20840865</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres J.E., Baldiris R., Vivas-Reyes R. Design of angiotensin-converting enzyme 2 (ACE2) inhibitors by virtual lead optimization and screening. J. Chin. Chem. Soc. 2012 Nov;59(11):1394–1400. doi: 10.1002/jccs.201200079. Epub 2012 Jul 23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jccs.201200079</ArticleId><ArticleId IdType="pmc">PMC7166750</ArticleId><ArticleId IdType="pubmed">32336762</ArticleId></ArticleIdList></Reference><Reference><Citation>Dales N.A., Gould A.E., Brown J.A., Calderwood E.F., Guan B., Minor C.A., Gavin J.M., Hales P., Kaushik V.K., Stewart M., Tummino P.J., Vickers C.S., Ocain T.D., Patane M.A. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J. Am. Chem. Soc. 2002 Oct 9;124(40):11852–11853. doi: 10.1021/ja0277226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja0277226</ArticleId><ArticleId IdType="pubmed">12358520</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadah L.M., Deiab G.I.A., Al-Balas Q., Basheti I.A. Carnosine to combat novel coronavirus (nCoV): molecular docking and modeling to cocrystallized host angiotensin-converting enzyme 2 (ACE2) and viral spike protein. Molecules. 2020 Nov 28;25(23):5605. doi: 10.3390/molecules25235605.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25235605</ArticleId><ArticleId IdType="pmc">PMC7730390</ArticleId><ArticleId IdType="pubmed">33260592</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadah L., Abu Deiab G., Basheti I., Al-Balas Q.  World Intellectual Property Organization; 2023. WO2023238167 - Compounds and Pharmaceutical Compositions for Treating Coronavirus Disease and Methods of Preparation Thereof.https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023238167&amp;_cid=P21-LQ5905-72783-1 Available at:</Citation></Reference><Reference><Citation>Habra K., Pearson J.R.D., Le Vu P., Puig-Saenz C., Cripps M.J., Khan M.A., Turner M.D., Sale C., McArdle S.E.B. Anticancer actions of carnosine in cellular models of prostate cancer. J. Cell Mol. Med. 2024 Jan;28(2) doi: 10.1111/jcmm.18061. Epub 2023 Nov 29. PMID: 38018900; PMCID: PMC10826443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.18061</ArticleId><ArticleId IdType="pmc">PMC10826443</ArticleId><ArticleId IdType="pubmed">38018900</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W., Liu H., Li X., Ooi T.C., Rajab N.F., Cao H., Sharif R. Efficacy of zinc carnosine in the treatment of colorectal cancer and its potential in combination with immunotherapy in vivo. Aging (Albany NY) 2022 Nov 14;14(21):8688–8699. doi: 10.18632/aging.204380. Epub 2022 Nov 14. PMID: 36375474; PMCID: PMC9699748.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.204380</ArticleId><ArticleId IdType="pmc">PMC9699748</ArticleId><ArticleId IdType="pubmed">36375474</ArticleId></ArticleIdList></Reference><Reference><Citation>Morsy M.A., Kandeel M., Ibrahim A.R.N., Abdel-Gaber S.A., Jacob S., Venugopala K.N., Shinu P., El-Daly M. Carnosine potentiates doxorubicin-induced cytotoxicity in resistant NCI/ADR-RES cells by inhibiting P-Glycoprotein-In silico and in vitro evidence. Molecules. 2022 Oct 30;27(21):7383. doi: 10.3390/molecules27217383. PMID: 36364209; PMCID: PMC9659291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27217383</ArticleId><ArticleId IdType="pmc">PMC9659291</ArticleId><ArticleId IdType="pubmed">36364209</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.D., Sale C., Garner A.C., Hipkiss A.R. Anti-cancer actions of carnosine and the restoration of normal cellular homeostasis. Biochim. Biophys. Acta Mol. Cell Res. 2021 Oct;1868(11) doi: 10.1016/j.bbamcr.2021.119117. Epub 2021 Aug 10. PMID: 34384791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2021.119117</ArticleId><ArticleId IdType="pubmed">34384791</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Shen W., Liu T., Mosenthin R., Bao Y., Chen P., Hao W., Zhao L., Zhang J., Ji C., et al. Improved satellite cell proliferation induced by L-carnosine benefits muscle growth of pigs in part through activation of the Akt/mTOR/S6K signaling pathway. Agriculture. 2022;12(7):988. doi: 10.3390/agriculture12070988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/agriculture12070988</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartwright S.P., Bill R.M., Hipkiss A.R. L-carnosine affects the growth of Saccharomyces cerevisiae in a metabolism-dependent manner. PLoS One. 2012;7(9) doi: 10.1371/journal.pone.0045006. Epub 2012 Sep 12. PMID: 22984600; PMCID: PMC3440334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045006</ArticleId><ArticleId IdType="pmc">PMC3440334</ArticleId><ArticleId IdType="pubmed">22984600</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>